/
Oncology
Advanced or Metastatic Solid Tumors
100
Pipeline Programs↗
87
Active Trials↗
100
Companies Involved↗
Advanced or Metastatic Solid Tumors is a moderately active landscape with 100 programs across 100 companies. The most active players are Ono Pharmaceutical Co. Ltd, NGM Biopharmaceuticals, Inc, Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 158
Phase 228
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
82 of 89 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 89 classified programs, each share of the total. Modality classified for 95% of 100 pipeline programs.
Analysis
Trial Status
279
clinical trials
Completed118 · 42%
Recruiting57 · 20%
Terminated49 · 18%
Active, not recruiting18 · 6%
Unknown status17 · 6%
Not yet recruiting12 · 4%
Other8 · 3%
Clinical Trials
Trial Activity
279 trials
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)